ALLMedicine™ Agammaglobulinemia Center

Mar 24th, 2021 - Bruton's agammaglobulinemia tyrosine kinase (BTK) is an important cytoplasmic tyrosine kinase involved in B‑lymphocyte development, differentiation, and signaling. Activated protein kinase C (PKC), in turn, induces the activation of mitogen‑activa...

Mar 13th, 2021 - X-linked agammaglobulinemia is a rare primary immunodeficiency due to a BTK mutation. The patients are characteristically deficient in peripheral B cells and serum immunoglobulins. While they are susceptible to infections caused by bacteria, enter...

Mar 12th, 2021 - Metagenomic next-generation sequencing is a promising tool for detecting pathogens that are difficult to isolate by traditional modalities, particularly in the diagnosis of complex infections in immunocompromised children. We describe a child with...

Feb 22nd, 2021 - BACKGROUND Since the emergence of coronavirus disease 2019 (COVID-19), patients with the illness have presented with considerable variation in severity. Some infected individuals present mild or no symptoms, while others present severe illness wit...

Feb 11th, 2021 - Agammaglobulinemia with normal B-cell numbers in a patient lacking Bob1.|2021|Kury P,Staniek J,Wegehaupt O,Janowska I,Eckenweiler M,|

Mar 24th, 2021 - Bruton's agammaglobulinemia tyrosine kinase (BTK) is an important cytoplasmic tyrosine kinase involved in B‑lymphocyte development, differentiation, and signaling. Activated protein kinase C (PKC), in turn, induces the activation of mitogen‑activa...

Mar 21st, 2021 - GAMMAGARD LIQUID is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agamm...

Mar 21st, 2021 - CUVITRU is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Solution indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older. This includes, but is not limited to, co...

Mar 13th, 2021 - X-linked agammaglobulinemia is a rare primary immunodeficiency due to a BTK mutation. The patients are characteristically deficient in peripheral B cells and serum immunoglobulins. While they are susceptible to infections caused by bacteria, enter...

Mar 12th, 2021 - Metagenomic next-generation sequencing is a promising tool for detecting pathogens that are difficult to isolate by traditional modalities, particularly in the diagnosis of complex infections in immunocompromised children. We describe a child with...

Jan 14th, 2020 - Which of the following is the most likely diagnosis? Your Peers Chose: Bruton agammaglobulinemia 0% Thymoma 0% Pheochromocytoma 0% Teratoma 0% Discussion The patient in this case was eventually diagnosed with thymoma. Symptoms from a thymoma or th...

Jul 4th, 2019 - The US Food and Drug Administration (FDA) has approved a 20% immune globulin solution for subcutaneous injection (Xembify, Grifols) to treat primary immunodeficiencies in patients as young as 2 years old, according to a company statement. The appr...

Feb 9th, 2017 - Vials of product Photo by Bill Branson The US Food and Drug Administration (FDA) has approved an intravenous immunoglobulin (IVIG) product (Gammaplex® 10%) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenia (ITP.

Aug 7th, 2015 - Vials of drug Photo by Bill Branson The US Food and Drug Administration (FDA) has approved an intravenous human immune globulin (IVIG) product (Gammaplex) for pediatric patients age 2 years and older who have primary humoral immunodeficiencies. Th.

Sep 23rd, 2010 - September 24, 2010 — Octapharma USA is voluntarily withdrawing all lots of immune globulin G (IgG) intravenous (human) 5% liquid preparation (Octagam) in the United States while it investigates blood clots and embolisms linked with the biologic, t...